Politics · India Bureau
Supreme Court seeks accountability on medicine pricing practices
India's top court has questioned the government over alleged excessive markups on essential medicines, highlighting cases where private hospitals charge significantly more than procurement costs. The bench pointed to instances where anti-cancer drugs available at wholesale rates were sold to patients at multiples of their actual cost.
LSN India ·
The Supreme Court bench raised concerns during proceedings on medicine pricing, directing attention to the gap between procurement costs and retail prices charged by private healthcare facilities. In one example cited, a pharmaceutical distributor quoted an anti-cancer drug at ₹1,100, yet the same medication was dispensed to patients at private hospitals for ₹1.30 lakh—a markup of over 11,700 per cent.
The court's intervention underscores ongoing questions about price regulation in India's pharmaceutical sector, where the balance between manufacturer profitability, distributor margins, and patient affordability remains contentious. The wide discrepancy between wholesale and retail rates raises questions about whether existing price control mechanisms are functioning effectively.
The proceedings suggest the judiciary is examining whether government oversight of drug pricing adequately protects consumers from unreasonable charges, particularly for critical medications. The bench's line of questioning indicates potential pressure on authorities to strengthen monitoring and enforcement mechanisms in the healthcare supply chain.
The issue reflects broader concerns about healthcare accessibility in India, where medicine costs remain a significant burden for many patients. The court's scrutiny may prompt policy review on how pharmaceutical pricing is regulated and monitored across public and private healthcare systems.